Growth Metrics

Summit Therapeutics (SMMT) Share-based Compensation (2019 - 2025)

Summit Therapeutics' Share-based Compensation history spans 7 years, with the latest figure at $111.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 914.79% year-over-year to $111.8 million; the TTM value through Dec 2025 reached $732.4 million, up 1336.65%, while the annual FY2025 figure was $732.4 million, 1336.65% up from the prior year.
  • Share-based Compensation reached $111.8 million in Q4 2025 per SMMT's latest filing, down from $130.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $478.8 million in Q2 2025 to a low of $705000.0 in Q3 2023.
  • Average Share-based Compensation over 5 years is $41.1 million, with a median of $4.8 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: tumbled 74.8% in 2023, then soared 4218.04% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $5.6 million in 2021, then tumbled by 52.7% to $2.7 million in 2022, then soared by 229.31% to $8.8 million in 2023, then grew by 25.84% to $11.0 million in 2024, then skyrocketed by 914.79% to $111.8 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Share-based Compensation are $111.8 million (Q4 2025), $130.8 million (Q3 2025), and $478.8 million (Q2 2025).